Condition
Circulatory Shock
Total Trials
5
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 4 (1)
Trial Status
Completed1
Active Not Recruiting1
Unknown1
Withdrawn1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06376318Active Not RecruitingPrimary
Shock and Acute Conditions OutcOmes Platform
NCT05102734CompletedPrimary
Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock.
NCT06265259Phase 4RecruitingPrimary
Efficacy of the Use of Vasopressin as a Primary Vasoconstrictor in Critically Ill Patients
NCT04357275Unknown
The RIsk Stratification in COVID-19 Patients in the ICU Registry
NCT03483753Phase 2WithdrawnPrimary
Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery
Showing all 5 trials